Biotech entity
fda-approval is the sole category represented across all 1 tracked stories. Stephen Hoge is most often covered alongside Charbel Haber, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 6 original sources each against 2.5 for the same window.
Last mentioned: Aug 1, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
fda-approval is the sole category represented across all 1 tracked stories. Stephen Hoge is most often covered alongside Charbel Haber, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 6 original sources each against 2.5 for the same window. At 6, the average consequence score sits above the same-window beat average of 5.7. We currently track 1 Biotech story that mention Stephen Hoge, all published on August 1, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Stephen Hoge. Shared-story counts are live from our verified record — not editorial picks.
FDA Decision Deadline
The agency faces a deadline to approve or reject the vaccine.
Advisory Panel Recommends Approval
An FDA advisory panel votes in favor of approving the vaccine.
FDA Issues Refuse-to-File Letter
FDA informs Moderna it will not review the mRNA flu shot application, surprising the company after prior assurances.
FDA Accepts Application After Outcry
A little over a week later, the agency reverses its decision after Moderna commits to a confirmatory study.
After a shocking FDA refusal-to-file in February and a subsequent advisory panel endorsement, Moderna's experimental mRNA influenza vaccine faces a final decision on August 5. The outcome holds deep implications for the viability of mRNA technology beyond COVID-19 and the future of Moderna's pipeline diversification.
Source: news.wjct.org · wdiy.org
Stephen Hoge is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
